2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Adverse Events, Biological Processes, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Diseases, Lymphoid Malignancies, Myeloid Malignancies, Acute Myeloid Malignancies, Measurable Residual Disease, Research, AML, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult, Elderly, Young Adult
PAPER

3420 Post-transplant outcomes after venetoclax-based therapy versus conventional induction before allo-HSCT in AML: A propensity score-matched real-world analysis

Ranadheer Dande, MD FACP, Jennifer Elizabeth Collins, PhD2, Amir Kamran, MD3
1 Charleston Area Medical Center, Charleston, West Virginia, United States
2 Charleston Area Medical Center, Charleston, West Virginia, United States
3 Charleston Area Medical Center, Charleston, West Virginia, United States

Introduction: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains a potentially curative treatment for acute myeloid leukemia (AML), but relapse remains a major cause of treatment failure. Venetoclax-based regimens are increasingly used before transplantation, yet comparative post-transplant outcome data are limited. 

Methods: We performed a retrospective cohort study using the TriNetX Research Network to compare patients with AML from 2015-2025. Patients were divided into mutually exclusive cohorts based on receipt of venetoclax-based therapy before allo-HSCT vs receipt of conventional induction therapy. Before matching, 589 venetoclax-exposed and 1,217 conventional-induction patients were identified. Propensity score matching included age, sex, race, COPD, hypertension, liver disease, obesity, heart failure, diabetes, CAD, CKD, prior myelodysplastic syndrome, and prior myeloproliferative neoplasm. Matched cohorts were analyzed using Kaplan-Meier log rank tests within the TriNetX platform for hazard ratios (HRs) and 95% confidence intervals (CIs). Outcomes included overall survival (OS) and relapse-free survival (RFS) through 4 years, AML relapse from day 30 through 2 years, and graft-versus-host disease (GVHD) from day 1 through 1 year after allo-HSCT, excluding patients with existing GVHD.

Results: The analytic output included 448 matched patients per group. There was no significant difference in 4-year OS at 53.57% survival with venetoclax vs 56.95% with conventional induction therapy (log-rank p=0.424; HR = 1.09; 95% CI: 0.88–1.35). Four-year RFS was also not significantly different at 39.37% vs 42.58% (log-rank p=0.387; HR = 1.08; 95% CI: 0.90–1.30), with a median time to relapse of 527 versus 630 days (17.3 versus 20.7 months). In the AML relapse analysis, 146  venetoclax-exposed patients and 154 conventional-induction patients experienced relapse. Relapse hazard did not differ between groups (HR = 0.99; 95% CI: 0.79–1.24; log-rank p=0.944). In the GVHD analysis, 259 of 380 and 275 of 381 patients experienced GVHD, respectively, with no significant difference between groups (HR = 0.95; 95% CI: 0.80–1.13; log-rank p=0.549).

Discussion: In this propensity score-matched real-world cohort, patients receiving venetoclax before allo-HSCT was associated with similar 4-year OS and RFS and no statistically significant differences in post-transplant AML relapse or GVHD compared with conventional induction therapy. These findings suggest that a venetoclax-based pretransplant strategy does not compromise medium-term outcomes after allo-HSCT. Prospective studies are needed to validate these observations.

Ranadheer Dande, MD FACP: No relevant conflicts of interest to declare.